Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Chubb
Mallinckrodt
Daiichi Sankyo
Express Scripts
QuintilesIMS
Healthtrust
Cantor Fitzgerald
Chinese Patent Office

Generated: April 22, 2018

DrugPatentWatch Database Preview

PRIFTIN Drug Profile

« Back to Dashboard

Which patents cover Priftin, and what generic alternatives are available?

Priftin is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in PRIFTIN is rifapentine. One supplier is listed for this compound. Additional details are available on the rifapentine profile page.
Drug patent expirations by year for PRIFTIN
Pharmacology for PRIFTIN
Ingredient-typeRifamycins
Drug ClassRifamycin Antimycobacterial
Synonyms for PRIFTIN
(2R,16S,17R,18R,19R,20S,21S,22S,23S)-8-{[(4-CYCLOPENTYLPIPERAZIN-1-YL)IMINO]METHYL}-5,6,9,17,19-PENTAHYDROXY-23-METHOXY-2,4,12,16,18,20,22-HEPTAMETHYL-1,11-DIOXO-1,2-DIHYDRO-2,7-(EPOXYPENTADECA[1,11,13]TRIENOIMINO)NAPHTHO[2,1
(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-26-{(E)-[(4-cyclopentylpiperazin-1-yl)imino]methyl}-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1(4,7).0(5
[[(E)-(4-cyclopentylpiperazin-1-yl)iminomethyl]-pentahydroxy-methoxy-heptamethyl-dioxo-[?]yl] acetate
1279038-35-5
3-(((4-cyclopentyl-1-piperazinyl)imino)methyl)-rifamyci;3-(4-cyclopentyl-1-piperazinyl)iminomethylrifamycinsv
3-(((4-Cyclopentyl-1-piperazinyl)imino)methyl)rifamycin
3-(((4-cyclopentyl-1-piperazinyl)imino)methyl)rifamycin SV
3-(4-Cyclopentyl-1-piperazinyl)iminomethylrifamycin SV
3-(N-(4-Cyclopentyl-1-piperazinyl)formimidoyl)rifamycin
3-[N-(4-Cyclopentyl-1-piperazinyl)formimidoyl]rifamycin
379R655
61379-65-5
71950-35-1
773848-08-1
AK326142
AKOS024255723
Ambap127923-87-9
AN-15578
Antibiotic DL 473IT
C08059
C47H64N4O12
CCG-220467
CHEBI:45304
CHEMBL1660
Cyclopentyl rifampin
Cyclopentylrifampicin
D00879
D02AON
D0G9IU
DB01201
DL 473
DL 473-IT
DL-4-73
DL-473
DL473
DRG-0283
EINECS 262-743-9
J90035
KS-1409
KTC 1
M000473
MDL 473
MDL-473
MDL473
MFCD00866806
Priftin (TN)
Priftin, Cyclopentylrifampicin, Rifapentine
R 77-3
R-773
Retinal pigment epithelium
Rifamycin AF/ACPP
Rifamycin, 3-(((4-cyclopentyl-1-piperazinyl)imino)methyl)-
Rifapentin
Rifapentina
Rifapentina [Spanish]
RIFAPENTINE
Rifapentine (USAN/INN)
Rifapentine [USAN:BAN:INN]
Rifapentine [USAN:INN:BAN]
Rifapentinum
Rifapentinum [Latin]
RISDZDVHYCURHD-QLWTZYDESA-N
RPE
RPT
UNII-XJM390A33U
XJM390A33U

US Patents and Regulatory Information for PRIFTIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us PRIFTIN rifapentine TABLET;ORAL 021024-001 Jun 22, 1998 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Healthtrust
UBS
QuintilesIMS
Chinese Patent Office
Merck
AstraZeneca
Harvard Business School
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.